Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MIF | P14174 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19052803 | 1.00 | BRD4 (0.51) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL31645448 | 0.89 | BRD4 (0.49) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL30045918 | 0.89 | BRD4 (0.49) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL337398 | 0.89 | BRD4 (0.49) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL337416 | 0.89 | BRD4 (0.50) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL10413120 | 0.88 | BRD4 (0.47) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL756256 | 0.84 | BRD4 (0.58) | BRD4GAAMIFHDAC6TSHR | |
| SCHEMBL6520162 | 0.82 | TSHR (0.40) | BRD4THRBALDH1A1TDP1MAPT | |
| SCHEMBL27313851 | 0.82 | KMT2A (0.40) | BRD4THRBALDH1A1TDP1POLB | |
| SCHEMBL11444638 | 0.77 | TDP1 (0.42) | ALDH1A1TDP1POLBMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2814834-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | Bristol-Myers Squibb Company (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8906889-B2 | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| CN-100390140-C | Nitrile compounds and their use in pest control | SUMITOMO CHEMICAL CO (JP) | 2008-05-28 | — | — | CN | disclosed |
| US-20070112068-A1 | Nitrile compound and its use in pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112068-A1 | Nitrile compound and its use in pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| US-3953377-A | Ethyl-2-trans-4-cis undecadienoate, ethyl-2-trans-4-cis dodecadienoate and ethyl-2-decadienoate perfume compositions | FIRMENICH S.A. (CH) | 1976-04-27 | — | — | US | disclosed |
| US-3941828-A | Process for the preparation of cyclic ketones | FIRMENICH SA (CH) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112068-A1 | Nitrile compound and its use in pest control | C5, C9, C1S | BRD4 1585/4885THRB 2584/4885ALDH1A1 2441/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | BRD4 2957/4885THRB 4214/4885ALDH1A1 539/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | BRD4 114/4885THRB 1850/4885ALDH1A1 1077/4885 |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | BRD4 388/4885THRB 3757/4885ALDH1A1 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.